Immatics N.V. (IMTX)
| Market Cap | 731.00M |
| Revenue (ttm) | 31.62M |
| Net Income (ttm) | -242.34M |
| Shares Out | 62.91M |
| EPS (ttm) | -21.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 22 |
| Last Price | $11.60 |
| Previous Close | $11.78 |
| Change ($) | -0.18 |
| Change (%) | -1.53% |
| Day's Open | 11.73 |
| Day's Range | 11.53 - 11.96 |
| Day's Volume | 48,367 |
| 52-Week Range | 8.66 - 18.42 |
Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirectin...
Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting...
Tuebingen, Germany and Houston, TX, March 30, 2021 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting ca...
Investors liked the company's latest clinical update.
A press release from the company is showing promise in shrinking cancerous tumors. The discoveries are leading to a rise in IMTX stock.
Immatics NV (NASDAQ: IMTX) has announced a clinical data update from the dose-escalation cohorts of the ongoing Phase 1 trial evaluating its ACTengine product candidates IMA201, IMA202, and IMA203. Data...
bluebird bio, Inc. (NASDAQ: BLUE), Onconova Therapeutics, Inc. (NASDAQ: ONTX), FSD Pharma Inc. (NASDAQ: HUGE) and Immatics N.V. (NASDAQ: IMTX) are among the biggest biopharma movers in Wednesday's session.
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fun...
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct therapeutic modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients ... [Read more...]
| Industry Biotechnology | |
| Stock Exchange NASDAQ | Ticker Symbol IMTX |
Financial Performance
In 2020, Immatics's revenue was $31.25 million, an increase of 69.40% compared to the previous year's $18.45 million. Losses were -$229.06 million, 625.5% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for Immatics stock is "Strong Buy." The 12-month stock price forecast is 23.75, which is an increase of 104.74% from the latest price.